Patents by Inventor Catherine R. O'Riordan

Catherine R. O'Riordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10821154
    Abstract: The present provides methods for treating spinal muscular atrophy using a self-complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administered the spinal column or cisterna magna in a human subject; for example, a pediatric human subject. Viral particles comprising AAV9 capsids are contemplated.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: November 3, 2020
    Assignee: Genzyme Corporation
    Inventors: Marco A. Passini, Lamya S. Shihabuddin, Catherine R. O'Riordan, Seng H. Cheng
  • Publication number: 20200225139
    Abstract: Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.
    Type: Application
    Filed: August 21, 2019
    Publication date: July 16, 2020
    Inventors: Catherine R. O'RIORDAN, Brenda BURNHAM
  • Publication number: 20200216848
    Abstract: Provided herein are RNAi molecules for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
    Type: Application
    Filed: September 21, 2018
    Publication date: July 9, 2020
    Inventors: Catherine R. O'RIORDAN, Adam PALERMO, Brenda RICHARDS, Lisa M. STANEK
  • Patent number: 10429288
    Abstract: Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: October 1, 2019
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, Brenda Burnham
  • Publication number: 20190055293
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: June 28, 2018
    Publication date: February 21, 2019
    Inventors: Catherine R. O'RIORDAN, William H. BRONDYK
  • Patent number: 10035829
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: July 31, 2018
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Publication number: 20180180525
    Abstract: Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.
    Type: Application
    Filed: January 19, 2016
    Publication date: June 28, 2018
    Applicants: Genzyme Corporation, Genzyme Corporation
    Inventors: Catherine R. O'RIORDAN, Brenda BURNHAM
  • Publication number: 20170369541
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: January 3, 2017
    Publication date: December 28, 2017
    Applicant: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Patent number: 9567382
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: February 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Publication number: 20160074474
    Abstract: The present provides methods for treating spinal muscular atrophy using a self-complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administered the spinal column or cisterna magna in a human subject; for example, a pediatric human subject. Viral particles comprising AAV9 capsids are contemplated.
    Type: Application
    Filed: May 1, 2013
    Publication date: March 17, 2016
    Applicant: Genzyme Corporation
    Inventors: Marco A. PASSINI, Lamya S. SHIHABUDDIN, Catherine R. O'RIORDAN, Seng H. CHENG
  • Publication number: 20110034546
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: April 15, 2009
    Publication date: February 10, 2011
    Applicant: GENZYME CORPORATION
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Publication number: 20030180261
    Abstract: The present invention relates to polymer-modified viruses, processes for obtaining them and their use. The invention also provides means of attaching polymer molecules to viral particles whereas retaining infectivity of the modified virus.
    Type: Application
    Filed: January 22, 2003
    Publication date: September 25, 2003
    Inventors: Alan E. Smith, Catherine R. O'Riordan, Gillian E. Francis, Vincent Parkes, Christina Delgado
  • Patent number: 6569426
    Abstract: Viruses are modified by coupling a polymer such as polyethylene glycol to obtain polymer-modified viruses that can exhibit reduced antigenicity while retaining infectivity, and which may exhibit increased circulation time in vivo. The polymer may be directly covalently attached or indirectly covalently attached via an intermediate coupling moiety to the virus. The polymer may also be indirectly noncovalently attached to the virus via a ligand such as an antibody having specificity for a viral surface component. To prepare the polymer-modified virus, the polymer is activated and coupled to the virus. A preferred activated polymer is tresyl-monomethoxypolyethylene glycol having an average molecular weight of about 5000 daltons. The polymer-modified viruses have utility for therapeutic and diagnostic in vivo applications, and may be used to introduce a transgene into a target cell by infection, or be administered to a subject having a tumor where the polymer-modified virus localizes to the tumor.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: May 27, 2003
    Assignees: Genzyme Corporation, Polymasc Pharmaceuticals
    Inventors: Alan E. Smith, Catherine R. O'Riordan, Gillian E. Francis, Vincent Parkes, Christina Delgado
  • Publication number: 20020034498
    Abstract: The present invention relates to polymer-modified viruses, processes for obtaining them and their use. The invention also provides means of attaching polymer molecules to viral particles whereas retaining infectivity of the modified virus.
    Type: Application
    Filed: September 30, 1999
    Publication date: March 21, 2002
    Inventors: ALAN E. SMITH, CATHERINE R. O'RIORDAN, GILLIAN E. FRANCIS, VINCENT PARKES, CHRISTINA DELGADO
  • Patent number: 6287857
    Abstract: This invention describes a nucleic acid delivery vehicle construct for transfecting and/or infecting a target cell. The construct is made of a delivery vehicle and a bifunctional complex for linking the delivery vehicle to a target cell. The bifunctional complex has a delivery vehicle-binding molecule or fragment (“delivery vehicle-binding portion”), a molecule or fragment thereof that binds to a cell surface molecule on the target cell (“cell surface molecule-binding portion”) and a linker which connects the molecules or fragments.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: September 11, 2001
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, Samuel C. Wadsworth
  • Patent number: 5939536
    Abstract: The present invention provides a method for purifying a membrane associated protein, e.g., cystic fibrosis transmembrane conductance regulator (hereinafter CFTR) in a functional form. The method involves contacting a membrane-associated protein-membrane fraction complex with a detergent forming a solubilized complex and chromatographically isolating the membrane-associated protein from the solubilized complex in a functional form. The functional form of the purified membrane-associated protein of the present invention preferably is sufficiently pure to allow its introduction into humans for therapeutic purposes.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: August 17, 1999
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, Amy L. Helgerson (Erickson)